Fablyn nedsatte signifikant forekomsten af non- vertebrale frakturer fra 10, 4% for placebo til 8, 1% for Fablyn (relativ reduktion af risiko = 24%, p = 0, 0020).
FABLYN significantly decreased the incidence of non-vertebral fractures from 10.4% for placebo to 8.1% for FABLYN (relative risk reduction = 24%, p = 0.0020).